

Despatch of Documents for Entitlement Offer

PainChek Ltd ACN 146 035 127 (ASX: PCK) (**PainChek** or **Company**) confirms that the Offer Booklet in respect of the Company's 1 for 20 pro rata non-renounceable entitlement offer, as announced to the ASX on 24 June 2022, was despatched via the Offer website at www.investorserve.com.au today. Eligible Shareholders have also been posted a personalised Entitlement and Acceptance Form.

Eligible Shareholders can request a hard copy of the Offer Booklet and their personalised Entitlement and Acceptance Form by contacting the PainChek Offer Information Line on 1300 737 760 (from within Australia) or +61 2 9290 9600 (from outside Australia) between 8.30am and 5.00pm (AEST), Monday to Friday during the Offer Period (10.00am on Monday, 4 July 2022 to 5.00pm on Wednesday, 27 July 2022).

For further enquiries, please contact the PainChek Offer Information Line on 1300 737 760 (from within Australia) or +61 2 9290 9600 (from outside Australia) between 8.30am and 5.00pm (AEST), Monday to Friday during the Offer Period (10.00am on Monday, 4 July 2022 to 5.00pm on Wednesday, 27 July 2022).

Authorised by:

The Board of Directors, PainChek Ltd

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com